N
ALDX icon

Nuveen’s Aldeyra Therapeutics ALDX Stock Holding History

Nuveen’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$35.9K Sell
21,266
-86,954
-80% -$381K ﹤0.01% 3215
2025
Q4 		$561K Sell
108,220
-36,465
-25% -$187K ﹤0.01% 2830
2025
Q3 		$755K Buy
144,685
+37,980
+36% +$198K ﹤0.01% 2748
2025
Q2 		$409K Sell
106,705
-241,816
-69% -$625K ﹤0.01% 2947
2025
Q1 		$10M Buy
348,521
+218,797
+169% +$1.29M ﹤0.01% 1551
2024
Q4 		$647K Hold
129,724
– – ﹤0.01% 2886
2024
Q3 		$699K Hold
129,724
– – ﹤0.01% 2896
2024
Q2 		$429K Hold
129,724
– – ﹤0.01% 3043
2024
Q1 		$424K Hold
129,724
– – ﹤0.01% 3022
2023
Q4 		$455K Sell
129,724
-56,252
-30% -$174K ﹤0.01% 3037
2023
Q3 		$1.24M Buy
185,976
+56,523
+44% +$419K ﹤0.01% 2483
2023
Q2 		$1.09M Buy
+129,453
New +$1.28M ﹤0.01% 2621
2022
Q2 		– Sell
-237,359
Closed -$1.14M – 3235
2022
Q1 		$1.14M Buy
237,359
+662
+0.3% +$2.64K ﹤0.01% 2772
2021
Q4 		$1.55M Sell
236,697
-12,238
-5% -$93.3K ﹤0.01% 2691
2021
Q3 		$2.13M Sell
248,935
-99,190
-28% -$910K ﹤0.01% 2644
2021
Q2 		$3.94M Buy
+348,125
New +$4.19M ﹤0.01% 2362
2020
Q2 		– Sell
-61,063
Closed -$151K – 3272
2020
Q1 		$151K Sell
61,063
-78,319
-56% -$352K ﹤0.01% 3031
2019
Q4 		$810K Buy
139,382
+64,863
+87% +$375K ﹤0.01% 2757
2019
Q3 		$393K Buy
74,519
+8,826
+13% +$47.5K ﹤0.01% 3006
2019
Q2 		$394K Buy
+65,693
New +$494K ﹤0.01% 3073

Other funds holding ALDX

KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Nuveen's ALDX Position: Q1 2026 in Review

Nuveen reduced its Aldeyra Therapeutics (ALDX) stake by 80% in Q1 2026, selling an estimated $381K and leaving 21,266 shares worth $35.9K. The position accounts for ﹤0.01% of the portfolio, ranked #3215.

Nuveen first reported a position in ALDX in Q2 2019 and has held it in 20 quarters since. The position peaked at $10M in Q1 2025. 126 funds tracked by Wall St. Rank hold ALDX as of Q1 2026.

  • Nuveen held 21,266 shares of Aldeyra Therapeutics worth $35.9K as of Q1 2026.
  • Nuveen sold 86,954 Aldeyra Therapeutics shares in Q1 2026, an estimated $381K.
  • Aldeyra Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q1 2026, its #3215 holding.
  • Nuveen first reported a position in Aldeyra Therapeutics in Q2 2019 and has held it in 20 quarters since.
  • Nuveen's Aldeyra Therapeutics position peaked at $10M in Q1 2025.
  • 126 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2026.

Based on Nuveen's 13F filing for Q1 2026, filed 30 Apr 2026.